Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Antiviral Res. 2019 May 31;168:134–145. doi: 10.1016/j.antiviral.2019.05.015

Figure 2. ONC201 has an antiviral effect against different primary HIV strains.

Figure 2.

A-C) Human MDM were plated in 96-well plates and infected with different primary HIV strains, including 2873MVC (HIV-1 Clade C strain, A), G0048CPX (HIV Clade B strain, B) and 2562BG (HIV Clade B strain, C) for 24 hours before incubation with doses of ONC201 or its isomer ranging from 3 to 30 μM. At 2-, 6-, 10-, and 14-day post ONC201 and isomer treatments, supernatants were collected and the replication levels of HIV-1 were monitored by RTase activity assay. Values represent SEM of biological replicates. Data were analyzed by two-way ANOVA: ** denotes p < 0.01, *** denotes p < 0.001, compared to the HIV-1+ONC201 isomer group of the same treatment dosage.